Literature DB >> 35082529

Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma.

Hua Zhao1, Benliang Lu2.   

Abstract

OBJECTIVE: To evaluate the predictive value of multiple serum tumor markers in hepatolithiasis complicated with intrahepatic cholangiocarcinoma (hepatolithiasis-associated cholangiocarcinoma, HL-CCA).
METHODS: From January 2010 to December 2020, three hundred eighty-five hepatolithiasis patients in Zhoukou Central Hospital were retrospectively analyzed, among them thirty patients complicated with intrahepatic cholangiocarcinoma. The levels of serum AFP, CA125, CA19-9, CA242, and CEA in hepatolithiasis or HL-CCA were measured. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic effects of single or combined detection of the five tumor markers for HL-CCA.
RESULTS: The level of AFP was insignificantly different between the hepatolithiasis and HL-CCA (P=0.730). CA125, CA19-9, CA242 and CEA were elevated in HL-CCA. The area under ROC curves (AUCs) of the single detection of serum CA125, CA19-9, CA242 and CEA were all more than 0.5. The maximum AUC occurred in CA19-9. The AUC of AFP was slightly higher than 0.5, but the level of serum AFP was insignificantly different between hepatolithiasis and HL-CCA. The single detection of AFP was not of great significance to the differential diagnosis. The optimal cut-off values of CA125, CA19-9, CA242, and CEA were 104.09 kU/L, 383.28 U/mL, 152.56 kU/L, 6.29 ng/mL. The diagnostic effect of CA19-9 was the highest one for differential diagnosis between hepatolithiasis and HL-CCA. With reference to CA19-9 >383.28 U/mL, the sensitivity and specificity of the single detection were 80.00% and 82.61% respectively, and the AUC was 0.883. The diagnostic effect of CEA was secondary toward CA19-9. With reference to CEA >6.29 ng/mL, the sensitivity and specificity of the single detection were 66.67% and 83.76% respectively, and the AUC was 0.814.
CONCLUSION: Serum CA19-9 maybe the effective tumor marker in the diagnosis of HL-CCA, and measurement of combined serum tumor markers can help in the detection of HL-CCA.
© 2022 Zhao and Lu.

Entities:  

Keywords:  ROC curve; cholangiocarcinoma; hepatolithiasis; tumor marker

Year:  2022        PMID: 35082529      PMCID: PMC8784971          DOI: 10.2147/CMAR.S344711

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  37 in total

Review 1.  Hepatolithiasis--epidemiology and pathogenesis update.

Authors:  Junichi Shoda; Naomi Tanaka; Toshiaki Osuga
Journal:  Front Biosci       Date:  2003-05-01

2.  Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.

Authors:  Franco Lumachi; Giovanni Lo Re; Renato Tozzoli; Federica D'Aurizio; Flavio Facomer; Giordano B Chiara; Stefano M M Basso
Journal:  Anticancer Res       Date:  2014-11       Impact factor: 2.480

3.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  State of serum markers for detection of cholangiocarcinoma.

Authors:  Sopit Wongkham; Atit Silsirivanit
Journal:  Asian Pac J Cancer Prev       Date:  2012

Review 6.  Tumor markers: myths and facts unfolded.

Authors:  S C Faria; T Sagebiel; M Patnana; V Cox; C Viswanathan; C Lall; A Qayyum; P R Bhosale
Journal:  Abdom Radiol (NY)       Date:  2019-04

7.  Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma.

Authors:  Satoki Kojima; Toru Hisaka; Ryuta Midorikawa; Yoshiki Naito; Jun Akiba; Masahiko Tanigawa; Hirohisa Yano; Yoshito Akagi; Koji Okuda
Journal:  Anticancer Res       Date:  2020-08       Impact factor: 2.480

8.  Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.

Authors:  Min Seong Kim; Tae Joo Jeon; Ji Young Park; Jeongmin Choi; Won Chang Shin; Seong Eun Park; Ji Young Seo; Young Moon Kim
Journal:  Korean J Gastroenterol       Date:  2017-08-25

Review 9.  Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.

Authors:  Long Ge; Bei Pan; Fujian Song; Jichun Ma; Dena Zeraatkar; Jianguo Zhou; Jinhui Tian
Journal:  BMJ Open       Date:  2017-12-26       Impact factor: 2.692

10.  CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.

Authors:  Sven H Loosen; Christoph Roderburg; Katja L Kauertz; Alexander Koch; Mihael Vucur; Anne T Schneider; Marcel Binnebösel; Tom F Ulmer; Georg Lurje; Wenzel Schoening; Frank Tacke; Christian Trautwein; Thomas Longerich; Cornelis H Dejong; Ulf P Neumann; Tom Luedde
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.